核酸新藥 · 從序列設計到候選新藥 Nucleic Acid Therapeutics · From Sequence Design to Drug Candidates

讓核酸新藥走進病人的治療選擇 Bringing Nucleic Acid Therapeutics into Treatment Choices for Patients

從序列設計到候選新藥，聚焦肝臟疾病治療方案。台灣基因核酸新藥股份有限公司（台基核, COGENTIDE）自主建立 ASO 核酸新藥設計與篩選平台，並以自建之免疫健全肝癌動物模式驗證候選藥物效力。 From sequence design to drug candidates — focused on treatment approaches for liver disease. Taiwan CoGentide Novel Drug Corp. (CoGentide) has independently built an ASO design and screening platform, and validated candidate efficacy using its proprietary immunocompetent liver cancer animal model.

認識核心能力Explore Our Core Capabilities 聯絡我們Contact Us
台基核核酸新藥，致力於守護病患與家庭的健康

深入了解台基核

Explore CoGentide

關於我們About Us

認識台基核的使命願景，以及核心能力的完整介紹。 Learn about our mission, vision, and core capabilities.

了解更多Learn more →

核心能力Core Capabilities

深入了解 ASO 篩選平台、動物模式驗證與法規開發路徑。 A closer look at our ASO screening platform, animal model validation, and regulatory pathway.

了解更多Learn more →

研發項目Pipeline

查看目前推進中的核酸新藥與新劑型開發專案進度。 See the current progress of our nucleic acid drug and formulation development programs.

了解更多Learn more →
肝臟疾病解決方案 Liver Disease Solutions

候選核酸新藥經由動物模式篩選驗證，目前聚焦於肝細胞癌（HCC）術後微量殘留疾病之治療，未來將視技術與資源進展逐步擴展適應症範圍。 Candidate nucleic acid drugs are validated through animal model screening, currently focused on the treatment of minimal residual disease (MRD) following hepatocellular carcinoma (HCC) resection. We plan to expand our indication scope as technology and resources allow.

查看研發項目View our programs

近期成果

Recent Progress

  • 1

    完成 ASO 設計演算法開發，並以 3 款上市藥物標靶序列驗證篩選能力 Completed development of the ASO design algorithm, validated against target sequences of 3 marketed drugs

  • 2

    已於多個肝癌細胞株中篩選出具潛力之 TERT ASO 候選序列，初步結果顯示具基因表現抑制活性，相關驗證仍在進行中 Identified promising TERT ASO candidate sequences across multiple liver cancer cell lines, with preliminary results showing gene-suppression activity; validation is ongoing

  • 3

    免疫健全 HBV 相關肝腫瘤動物模式建立完成，提出 PCT 及台灣發明專利申請 Completed development of the immunocompetent HBV-related liver tumor model; filed PCT and Taiwan patent applications

與我們展開合作對話 Let's Start a Conversation

無論是授權合作、共同開發，或學研合作，歡迎與我們的團隊聯繫，進一步了解台基核的核酸新藥開發進程。 Whether you're exploring licensing, co-development, or academic collaboration, we'd love to hear from you — and share more about where CoGentide's nucleic acid drug development stands today.

聯絡我們Contact Us